Status:
COMPLETED
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Lead Sponsor:
University of Baghdad
Conditions:
COVID 19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
Detailed Description
Comparing effectiveness of single dose 0.2mg/kg Ivermectin (IVM) plus hydroxychloroquine (HCQ) 400mg BID in first day then 200mg BID for 5 days plus azithromycin (AZT) 500mg in first day then 250mg fo...
Eligibility Criteria
Inclusion
- Patients with age above 18 years and any gender with definite Dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria.
- 2\. Understands and agrees to comply with planned study procedures.
Exclusion
- Patients with hypersensitivity or severe adverse effects to Ivermectin
- Renal impairment
- Hepatic impairment.
- Pregnancy or a desire to become pregnant (drug considered pregnancy category c)
- Breast feeding.
- Patient with covid 19 positive and mild no pneumonia
- Children under the age of five or those who weigh less than 15 kilograms
Key Trial Info
Start Date :
April 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04343092
Start Date
April 18 2020
End Date
June 1 2020
Last Update
November 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Directorate of Medical City
Baghdad, Baghdad Governorate, Iraq, 964